Publication:


abstract


Related Articles
125I-Labeled chimeric monoclonal antibody, ch806, targeting the epidermal growth factor receptor deletion variant de2-7 (EGFRvIII)
Molecular Imaging and Contrast...
125I-Labeled chimeric monoclonal antibody, ch806, targeting the epidermal growth factor receptor deletion variant de2-7 (EGFRvIII)
Chopra A. Molecular Imaging and Contrast Agent Database (MICAD). 2004
111In-Labeled CHX-A”-DTPA conjugated monoclonal antibody (mAb) 806 targeting the epidermal growth factor receptor deletion variant de2-7 (EGFRvIII)
Molecular Imaging and Contrast...
111In-Labeled CHX-A”-DTPA conjugated monoclonal antibody (mAb) 806 targeting the epidermal growth factor receptor deletion variant de2-7 (EGFRvIII)
Chopra A. Molecular Imaging and Contrast Agent Database (MICAD). 2004
125I-Labeled monoclonal antibody (mAb) 806 targeting the epidermal growth factor receptor deletion variant de2-7 (EGFRvIII)
Molecular Imaging and Contrast...
125I-Labeled monoclonal antibody (mAb) 806 targeting the epidermal growth factor receptor deletion variant de2-7 (EGFRvIII)
Chopra A. Molecular Imaging and Contrast Agent Database (MICAD). 2004
Review Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Drugs Today (Barc). 2005
Review Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J, Burtness B. Drugs Today (Barc). 2005 Feb; 41(2):107-27.
Review Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Pathol Res Pract. 2011
Review Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P, Gonzalez S. Pathol Res Pract. 2011 Jun 15; 207(6):337-42. Epub 2011 Apr 29.